Introducing Esopredict: A Major Advancement in Esophageal Health
Previse, a leader in gastrointestinal health, has recently released a significant study highlighting the capabilities of Esopredict, an advanced DNA methylation test specifically designed to identify patients with Barrett's esophagus (BE). This groundbreaking assay predicts which individuals are at risk of progressing to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), making it an essential resource for healthcare professionals.
Key Findings from the Study
The findings, published in the journal Diagnostics, emphasize the analytical validation of Esopredict, showcasing its dependability. Sarah Laun, PhD, VP of Research and Development at Previse, remarked, "This analytical validation study enhances the credibility of Esopredict's earlier clinical validation. The robust results confirm the assay's analytical performance conducted in our dedicated laboratory in Baltimore." The results reveal Esopredict's remarkable reproducibility and precision, demonstrating excellent performance across various risk levels.
The Importance of Early Detection
Esophageal cancer is one of the most challenging cancers worldwide, known for its high mortality rates. Patients with Barrett's esophagus have a significantly higher chance of developing HGD or EAC. Before the introduction of Esopredict, there was a lack of effective prognostic testing for this progression. Now, Esopredict aids gastroenterologists in accurately assessing individual patient risks, guiding tailored surveillance and treatment strategies that meet each patient's specific needs.
A Closer Look at Previse and Its Mission
Founded in 2018, Previse is committed to tackling chronic acid reflux diseases and cancers affecting the gastrointestinal tract. Their goal is to improve patient health outcomes through early detection and preventive strategies. With innovative biomarkers developed by researchers like Dr. Stephen Meltzer at Johns Hopkins University School of Medicine, Previse is dedicated to addressing the growing rates of GI diseases, especially esophageal cancer.
The Role of Esopredict in Treatment Approaches
Esopredict serves as a vital DNA methylation-based test that evaluates the likelihood of a patient's progression to high-grade dysplasia or esophageal adenocarcinoma, primarily among those with Barrett's esophagus. With a turnaround time of about two weeks, Esopredict allows gastroenterologists to effectively tailor their treatment plans. This timely information can be critical, leading to early intervention and better patient outcomes.
Contact Information and Resources
For more information about Esopredict and the detailed findings from the study, individuals can visit Previse's official website. This platform offers valuable insights and scientific updates that are important for both healthcare providers and patients.
Media Contact:
Rebekah Epstein
Previse's dedication to enhancing gastrointestinal health through innovative solutions places the company at the forefront of preventive care related to esophageal health.
Frequently Asked Questions
What is Esopredict?
Esopredict is a DNA methylation test designed to assess the risk of progression in patients diagnosed with Barrett's esophagus.
How does Esopredict work?
The assay analyzes specific DNA methylation patterns to evaluate the likelihood of a patient developing high-grade dysplasia or esophageal adenocarcinoma.
What are the benefits of using Esopredict?
Esopredict offers gastroenterologists a reliable method for stratifying patients' risk levels, enabling informed treatment and surveillance decisions.
Who developed Esopredict?
Esopredict is developed by Previse, which collaborates with researchers from Johns Hopkins University School of Medicine.
How quickly can results from Esopredict be obtained?
The turnaround time for Esopredict results is typically around two weeks, allowing for timely treatment interventions.
